Tamoxifen Therapy for Breast Cancer and Endometrial Cancer Risk

Leslie Bernstein, Dennis Deapen, James R. Cerhan, et. al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Share article


Reviewers: Li Liu, MD
Source: Journal of the National Cancer Institute, Volume 91, No 19:1654-1662, October 1999.

Background

Tamoxifen is now widely used among women of all ages for the treatment of all stages of breast cancer. Tamoxifen reduces the risk of breast cancer recurrences and mortality as well as subsequent contralateral breast cancer. However, it is also known that tamoxifen used for adjuvant therapy is associated with increasing risk of developing endometrial cancer. Other known risk factors associated with endometrial cancer include reproductive characteristics, obesity, hypertension, diabetes, use of steroid hormone preparations, and smoking. Whether these risk factors modify the tamoxifen-endometrial cancer relationship is unknown.

Methods

Dr. Bernstein and associates examined factors associated with the development of endometrial cancer in 324 patients with endometrial cancer and 671 matched controls. All patients were identified from within a population-based cohort of women diagnosed with breast cancer between 1978 and 1992.

Results

  • Tamoxifen use significantly increased the risk of endometrial cancer in these women, with an odds ratio of 1.52.

  • This risk increased with the duration of tamoxifen use, to an odds ratio of 4.06 in women treated for 5 years or more compared with nonusers.

  • A history of estrogen replacement therapy significantly increased the risk of endometrial cancer associated with tamoxifen use.

  • Higher body mass index also enhanced the risk, but this association was not statistically significant.

Discussion

This study confirmed the link between tamoxifen use and endometrial cancer, and added new knowledge of the risk-enhancing effects of treatment duration, body mass index, and estrogen replacement therapy. Closer monitoring of breast cancer patients with these risk factors may be indicated during tamoxifen therapy.


News
Three Medications Beneficial in Breast Cancer Prevention

Sep 22, 2014 - Three medications -- the selective estrogen receptor modulators tamoxifen and raloxifene, and tibolone, a drug not approved in the United States but used in many other countries to treat menopausal symptoms -- may reduce the risk for primary breast cancer. However, the three drugs are variously associated with an increased risk of thromboembolic events, endometrial cancer or stroke, according to a study published online Sept. 15 in the Annals of Internal Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More